Notice

Moxifloxacin solution for infusion, 400 mg/250 ml, 250 ml each; Meropenem, powder for injection/infusion, 1 g each; Vancomycin lyophilisate/powder for solution for infusion, 1000 mg each; Sulfamethoxazole/trimethoprim, concentrate for solution for infusion, … I will 80 mg/16 mg, 5 ml each. (INN: Moxifloxacin, ATX: J01MA14; INN: Meropenem, ATX: J01DH02; INN: Vancomycin, ATX: J01XA01; INN: Sulfamethoxazole and trimethoprim, ATX: J01EE01). (Nomenclature position code: DK 021:2015 33650000-1 “General anti-infectives for systemic use, vaccines, antineoplastic agents and immunomodulators”; DK 021:2015 33650000-1 “General anti-infectives for systemic use, vaccines, antineoplastic agents and immunomodulators”; DK 021:2015 33650000-1 “General anti-infectives for systemic use, vaccines, antineoplastic agents and immunomodulators”; DK 021:2015 33650000-1 “General anti-infectives for systemic use, vaccines, antineoplastic agents and immunomodulators”).

Details Subscribe

Countries:

Original Site Publication Date:

2026-01-09 00:00:00

Create/Change Date:

2026-01-09 08:30:35

Deadline:

2026-01-12 00:00:00

Original Language:

Procurement Method:

Other

Notice Type:

Invitation for Bids

Notice Status:

Published

Infusion solutions